Multiple Myeloma Research Foundation (MMRF) and Multiple Myeloma Research Consortium (MMRC) Highlighted in 10 Abstracts to be Presented at the 55th American Society of Hematology (ASH) Annual Meeting

Presentations include findings from interim analysis of landmark MMRF CoMMpassâ„  study, early-stage clinical trials, and analyses of samples from tissue bank

Norwalk, CT — December 5, 2013

The Multiple Myeloma Research Foundation (MMRF) and its affiliate organization and clinical research network the Multiple Myeloma Research Consortium (MMRC) today announced that 10 abstracts from their research and development collaborations with academia and industry have been accepted for oral and poster presentations at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition to be held December 7 - 10, 2013 in New Orleans, LA.

In an oral presentation, the MMRF will highlight an interim analysis of the groundbreaking MMRF CoMMpassSM (Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile) study, which is collecting cutting-edge, comprehensive clinical information and molecular profiling of 1,000 newly diagnosed patients over a minimum of eight years. CoMMpass will provide researchers with insights into patients’ disease progression and their responsiveness to specific treatment regimens, thereby characterizing the subtypes of multiple myeloma and enabling individualized treatment approaches. The initial data presented at ASH has been made publically available through the MMRF Researcher Gateway at www.mmrfresearchergateway.org – providing the entire worldwide myeloma community the ability to analyze the results.

Five MMRC presentations will include data from multiple myeloma trials conducted within the MMRC network in both newly diagnosed patients and patients with relapsed and/or refractory multiple myeloma. Among these presentations, Abstracts 1969 and 3220 will focus on data from new studies of Pomalyst (pomalidomide) and Kyprolis (carfilzomib), both of which were recently approved by the U.S. Food and Drug Administration based on data from MMRC trials. Abstracts 1938, 1976 and 535 will present data on investigational agents alone and in combination with approved drugs for treatment of multiple myeloma.

“The MMRC data presented at ASH represent the some of the most promising myeloma treatments in the pipeline, and we are so grateful for the unrelenting commitment of our partners who contributed to these trials,” said Walter M. Capone, Chief Operating Officer of the MMRF. “We are also particularly proud to showcase on the progress on the MMRF CoMMpass study which will undoubtedly lead to advances in precision medicine approaches for myeloma patients.”

Additionally, three of the abstracts (1854, 534 and 4449) analyzed tissue samples from the MMRC Tissue Bank as part of the MMRF Multiple Myeloma Genomics Initiative. Abstract 531 will present data from a 2012 MMRF Research Fellow Award.

MMRF and MMRC presentations at ASH will include:

Abstract #: 1854


High Risk Multiple Myeloma Cases Are Identified In An MMRC Led Study By The SKY92 Gene Signature (MMprofiler)

Poster Session:

651. Myeloma: Biology and Pathophysiology, excluding Therapy: Genomics: Poster I

Date and Time:

Saturday, December 7, 2013, from 5:30 - 7:30 PM


Hall G (Ernest N. Morial Convention Center)


About the Multiple Myeloma Research Foundation (MMRF)
The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)(3) non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure. As the world's number-one private funder of multiple myeloma research, the MMRF has raised more than $240 million since its inception and directs 90% of total budget to research and related programming. As a result, the MMRF has been awarded Charity Navigator’s coveted four-star rating for 11 consecutive years, the highest designation for outstanding fiscal responsibility and exceptional efficiency. For more information about the MMRF, please visit: www.themmrf.org.

About the Multiple Myeloma Research Consortium
The Multiple Myeloma Research Consortium (MMRC) is a 509(a)(3) non-profit organization that integrates leading academic institutions to accelerate drug development in multiple myeloma. It is led from MMRC offices in Norwalk, Conn., and comprises 16 member institutions: Barbara Ann Karmanos Cancer Institute, Baylor Charles A. Sammons Cancer Center at Dallas, City of Hope, Dana-Farber Cancer Institute, Emory University's Winship Cancer Institute, the John Theurer Cancer Center at Hackensack University Medical Center, Mayo Clinic, Mount Sinai School of Medicine, Ohio State University, Sarah Cannon Research Institute, University Health Network (Princess Margaret Hospital), University of California-San Francisco, University of Chicago, University of Michigan, Virginia Cancer Specialists, and Washington University in St. Louis. The MMRC is the only consortium to join academic institutions through membership agreements, customized IT systems, and an integrated tissue bank. For more information, please visit www.themmrc.org.

Media contacts:
Anne Quinn Young